Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Leukemia. 2015 Jul 31;29(10):2062–2068. doi: 10.1038/leu.2015.212

Figure 2. Skin and intestinal GvHD responds to ruxolitinib.

Figure 2

A: A representative patient with cutaneous acute GVHD is shown prior and 1 week after ruxolitinib.

B: A representative patient with cutaneous chronic GVHD is shown prior and 3 weeks after ruxolitinib.

C: Serial biopsies of the intestinal tract of a patient with GVHD is displayed. Biopsies were taken 1 day prior to start of ruxolitinib and 4 weeks after ruxolitinib had been started.